Preclinical News and Research

RSS

New cancer research findings presented at 53rd ASH annual meeting

Researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine presented new research findings in 25 presentations this weekend at the 53rd Annual Meeting of the American Society of Hematology (ASH) at the San Diego Convention Center.

12 Dec 2011

Positive data from Aeterna Zentaris AEZS-131 preclinical study on TNBC

Aeterna Zentaris Inc. today announced positive preclinical data in triple-negative breast cancer (TNBC) for its highly selective Erk 1/2 inhibitor anticancer compound, AEZS-131.

11 Dec 2011

Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC

Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.

9 Dec 2011

Galectin Therapeutics to initiate GM-CT-01 Phase 1/2 combination study in advanced MM

Galectin Therapeutics, the Cancer Centre at the Cliniques universitaires Saint-Luc and the Ludwig Institute for Cancer Research (LICR) announced today that they will initiate a Phase 1/2 safety and efficacy trial testing a novel treatment combination in patients with advanced metastatic melanoma.

9 Dec 2011

ChemoCentryx commences CCX140 Phase II trial in diabetic nephropathy

ChemoCentryx, Inc. today announced the initiation of a Phase II clinical trial for CCX140, an orally-administered small molecule for the treatment of diabetic kidney disease.

9 Dec 2011

Euthymics presents EB-1020 preclinical data on ADHD at ACNP annual meeting

Euthymics Bioscience, Inc. today announced that it has presented preclinical data demonstrating that EB-1020, a next-generation product candidate for adult attention deficit/hyperactivity disorder (ADHD), may be effective for treating ADHD without the burden of drug abuse liability.

8 Dec 2011

ZIOPHARM receives European patent allowance for palifosfamide to treat cancer

ZIOPHARM Oncology, Inc. announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to pharmaceutical compositions of a novel DNA cross-linker, including palifosfamide and their use in treating cancer.

7 Dec 2011

TAU develops tumor destruction method that also creates immunity

Even when surgical tumor removal is combined with a heavy dose of chemotherapy or radiation, there's no guarantee that the cancer will not return. Now researchers at Tel Aviv University are strengthening the odds in favor of permanent tumor destruction - and an immunity to the cancer's return - with a new method of tumor removal.

7 Dec 2011

Global problem of fatal snakebites and promising solutions highlighted at ASTMH meeting

Fatal snakebites are a bigger-than-acknowledged global health problem that has been vastly under-reported, according to research presented today at the American Society of Tropical Medicine and Hygiene's (ASTMH) annual meeting.

6 Dec 2011

EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it is presenting the comprehensive analysis of a recently completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia at the American College of Neuropsychopharmacology 50th Anniversary Annual Meeting.

5 Dec 2011

Fatal snakebites emerging global threat

5 Dec 2011

Growth hormone PDGF-BB and blood protein EPO implicated in development of cancer

Researchers at the Swedish medical university Karolinska Institutet have demonstrated that a growth hormone, PDGF-BB, and the blood protein EPO are involved in the development of cancer tumours and that they combine to help the tumours proliferate in the body.

5 Dec 2011

Spectrum seeks FDA IND approval for SPI-014 to treat hyperphosphatemia

Spectrum Pharmaceuticals today announced that it has submitted an investigational new drug (IND) application to the U.S. Food & Drug Administration for SPI-014 (previously referred to as RENAZORB), a second-generation lanthanum-based nanoparticle phosphate binding agent, that has the potential to treat hyperphosphatemia in patients with Stage 5 chronic kidney disease, or end-stage renal disease (ESRD).

5 Dec 2011

Researchers identify ADHD gene variants involved in glutamate signaling

Pediatric researchers analyzing genetic influences in attention-deficit/hyperactivity disorder (ADHD) have found alterations in specific genes involved in important brain signaling pathways. The study raises the possibility that drugs acting on those pathways might offer a new treatment option for patients with ADHD who have those gene variants—potentially, half a million U.S. children.

5 Dec 2011

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

HRF inhibitors may provide new therapeutic avenue for treatment of asthma and allergies

La Jolla Institute for Allergy & Immunology scientists have identified the histamine releasing factor (HRF) molecule as a promising target for developing new treatments for a number of allergic reactions including asthma.

3 Dec 2011

La Jolla researchers create first cellular movies showing destruction underlying type 1 diabetes

A war is being waged in the pancreases of millions of people throughout the world. The siege leads to the development of type 1 diabetes and has been a battlefield largely hidden from view-- until now.

3 Dec 2011

New technique allows production of medically useful amounts of endoderm cells from human PSCs

Scientists in Canada have overcome a key research hurdle to developing regenerative treatments for diabetes and liver disease with a technique to produce medically useful amounts of endoderm cells from human pluripotent stem cells. The research, published in Biotechnology and Bioengineering, can be transferred to other areas of stem cell research helping scientists to navigate the route to clinical use known as the 'valley of death'.

3 Dec 2011

Synthetic human tissue aids in testing photoacoustic and ultrasonic imaging technologies

The precise blending of tiny particles and multicolor dyes transforms gelatin into a realistic surrogate for human tissue. These tissue mimics, known as "phantoms," provide an accurate proving ground for new photoacoustic and ultrasonic imaging technologies.

1 Dec 2011

Statens Serum Institut, Aeras initiate new candidate TB vaccine Phase I trial

Statens Serum Institut and Aeras today announce the initiation of the first Phase I clinical trial of a new candidate TB vaccine designed to protect people latently infected with TB from developing active TB disease.

1 Dec 2011

Preclinical News and Research

New cancer research findings presented at 53rd ASH annual meeting

Positive data from Aeterna Zentaris AEZS-131 preclinical study on TNBC

Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC

Galectin Therapeutics to initiate GM-CT-01 Phase 1/2 combination study in advanced MM

ChemoCentryx commences CCX140 Phase II trial in diabetic nephropathy

Euthymics presents EB-1020 preclinical data on ADHD at ACNP annual meeting

ZIOPHARM receives European patent allowance for palifosfamide to treat cancer

TAU develops tumor destruction method that also creates immunity

Global problem of fatal snakebites and promising solutions highlighted at ASTMH meeting

EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting

Fatal snakebites emerging global threat

Growth hormone PDGF-BB and blood protein EPO implicated in development of cancer

Spectrum seeks FDA IND approval for SPI-014 to treat hyperphosphatemia

Researchers identify ADHD gene variants involved in glutamate signaling

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

HRF inhibitors may provide new therapeutic avenue for treatment of asthma and allergies

La Jolla researchers create first cellular movies showing destruction underlying type 1 diabetes

New technique allows production of medically useful amounts of endoderm cells from human PSCs

Synthetic human tissue aids in testing photoacoustic and ultrasonic imaging technologies

Statens Serum Institut, Aeras initiate new candidate TB vaccine Phase I trial

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics